MOUD Buprenorphine Subli denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for moud buprenorphine subli are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Issued This Denial

Aetna requires prior authorization (PA) for sublingual buprenorphine when used for Medication for Opioid Use Disorder (MOUD). This is one of the most common reasons a buprenorphine claim is initially rejected. The denial does not mean the medication is not covered — it means the prescription was dispensed before Aetna confirmed coverage in advance.

Importantly, federal parity law (MHPAEA) requires that any PA process applied to MOUD be no more burdensome than prior authorization requirements applied to analogous treatments for other chronic medical conditions. This is a powerful argument if Aetna's PA criteria go beyond what the FDA-approved prescribing label or applicable clinical guidelines require.

## Why This Denial Is Appealable

Prior-auth denials are routinely overturned when the clinical record documents that the patient meets the coverage criteria Aetna set out in its own published policy. If the PA was simply not filed in advance, a retrospective appeal requesting exception to the timeliness rule on medical grounds is also available.

## Federal Appeal Framework

• Internal appeal (Level 1): File within the timeframe in your denial letter. Aetna must decide within 30 days (non-urgent) or 72 hours (urgent/expedited).
• External review (ACA §2719 / ERISA §503): After exhausting internal appeals, you may request independent external review — generally within four months of the final internal denial (verify the exact deadline on your letter). An IRO reviews whether Aetna's PA decision was consistent with its own criteria and with generally accepted medical practice.
• Expedited option: Request expedited review if delay would seriously harm health.

## Concrete Appeal Steps

1. Obtain Aetna's clinical coverage/medical policy for buprenorphine MOUD — this document lists every PA criterion Aetna applies. 2. Have your prescriber write a detailed medical-necessity letter addressing each criterion in that policy, citing specific chart entries by date. 3. Include documentation of the opioid use disorder diagnosis, prior treatment history, and clinical severity. 4. If the PA criteria are more restrictive than the FDA-approved label criteria, include a MHPAEA parity challenge. 5. Escalate to external review if the internal appeal is denied.

## Documentation to Gather

• Aetna's published PA criteria / clinical policy for buprenorphine MOUD
• Prescriber's medical-necessity letter mapping each criterion to chart documentation
• Diagnosis records confirming opioid use disorder
• Prior treatment history (other MOUD options tried, outcomes, dates)
• Clinical severity documentation (chart notes, standardized assessment scores if used)
• FDA prescribing information for the specific product

## Criteria-Mapping Structure

For every requirement in Aetna's PA policy, document the chart evidence that satisfies it:

| Aetna PA Requirement | Chart Evidence | |---|---| | Confirmed OUD diagnosis | Dated chart note with ICD-10 code | | Prescriber qualification (X-waiver / DATA 2000) | Prescriber credentials on record | | Treatment plan on file | Signed treatment agreement / care plan | | Prior treatment history (if required) | List of prior treatments with dates/outcomes |